Original scientific paper
https://doi.org/10.2478/aiht-2020-71-3378
ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients
Davorka Sutlović
orcid.org/0000-0002-9899-5119
; University of Split Department for Health Studies, Split, Croatia 2 University of Split School of Medicine, Department of Toxicology and Pharmacogenetics, Split, Croatia
Željko Ključević
; Public Health Institute of the Split-Dalmatia County, Department of Mental Health, Prevention and Outpatient Addiction Treatment, Split, Croatia
Sendi Kuret
; University of Split Department for Health Studies, Split, Croatia, 4 University Hospital Centre Split, Department of Pathology and Forensic Medicine, Split, Croatia
Abstract
The aim of this study was to determine the influence of ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms on methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT).The study included 35 participants undergoing MMT, who were divided in three groups: HCV-positive (N=12), HCVnegative (N=16), and HCV clinical remission (CR) (N=7). The concentrations of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were determined with gas chromatography-mass spectrometry. The patients were genotyped for ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 rs2242480, and CYP3A4 rs2740574 polymorphisms. Differences between single nucleotide polymorphism (SNP) genotypes and methadone-to-EDDP ratio were analysed with one-way ANOVA, which showed no significant difference between the genes (p=0.3772 for ABCB1 rs1045642, p=0.6909 for CYP2B6 rs3745274, and p=0.6533 for CYP3A4 rs2242480). None of the four analysed SNP genotypes correlated with methadone-to-EDDP concentration ratio. A major influence on it in hepatitis C-positive patients turned out to be the stage of liver damage.
Keywords
EDDP; genotyping; hepatitis C; liver damage; SNP
Hrčak ID:
248053
URI
Publication date:
23.12.2020.
Visits: 1.906 *